Radiotherapy combined with temozolomide treatment for glioblastoma multiforme: A meta-analysis

Tumor

Volumn 30, Issue 12, 2010, Pages 1056-1064

  Wang, Xiao Hu ^a,b   Guo, Li Yun ^a   Ma, Bin ^a   Yang, Ke Hu ^a   Zhang, Qiu Ning ^b   Cao, Nong ^a   Ye, Xiu Peng ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b Tumor Hospital of Gansu Province   (China)

Author keywords

Glioblastoma; Meta analysis; Radiotherapy; Randomized controlled trial; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COMPUTER PROGRAM; DRUG EFFICACY; DRUG SAFETY; EMBASE; FULL TEXT DATABASE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SCIENTIFIC LITERATURE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 78751699053     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2010.12.013     Document Type: Article

References (31)

1. LOUIS D N, OHGAKI H, WIESTLER O D, et al. The 2007 WHO classification of tumours of the central nervous system [J]. Acta Neuropathol, 2007, 114(2): 97-109. (Pubitemid 47103521)
2. CBTRUS 2008 statistical report: primary brain tumors in the United States, 1998-2002. Central Brain Tumor Registry of the United States. 2000-2004 [EB/OL]. [2008-07-7]. http://www.cbtrus.org/reports/2007-2008/2007report.pdf.
3. DEANGELIS L M. Brain tumars [J]. N Engl J Med, 2001, 344 (2): 114-123.
4. KORTMANN R D, JEREMIC B, WELLER M, et al. Radiochemotherapy of malignant glioma in adults. Clinical experiences [J]. Strahlenther Oncol, 2003, 179 (4): 219-232.
5. MAHALEY MS J R, METTLIN C, NATARAJAN N, et al. National survey of patterns of care for brain tumor patients [J]. J Neurosurg, 1989, 71(6): 826-836.
6. WALKER M D, ALEXANDER E J R, HUNTWE, et al. Evaluation of BCNU and /or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial [J]. J Neurosurg, 1978, 49 (3): 333-343.
7. LAPERRIERE N, ZURAW L, CAIRNCROSS G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review [J]. Radiather Oncol, 2002, 64(3): 259-273.
8. STEWART L A. Chemotherapy in adult highgrade glioma: A systematic review and meta analysis of individual patient data from 12 randomized trials [J]. Lancet, 2002, 359(9311): 1011-1018.
9. HIGGINS JPT, GREEN S(EDITORS). Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008)[EB/OL]. [2008-07-7]. http://www.cochrane-hand-book.org.
10. Review Manager (RevMan) (Computer program). Version 5.0.0 for Windows [M]. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
11. ATHANASSIOU H, SYNODINOU M, MARAGOUDAKIS E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme [J]. J Clin Oncol, 2005, 23 (10): 2372-2377.
12. KOCHER M, FROMMOLT P, BORBERG SK, et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma [J]. Strahlenther Onkolo, 2008, 184(11): 572-579.
13. ATHANASSIOU H, SYNODINOU M, MARAGOUDAKIS E, et al. Temozolomide (TMZ) combined with radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): a randomized phase III study [abstract] [J]. Eur J Cancer, 2003, S95.
14. STUPP R, MASON W P, VAN DEN BENT M J, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J]. N Engl J Med, 2005, 352 (10): 987-996.
15. MIRIMANOFF R O, GORLIA T, MASON W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial [J]. J Clin Oncol, 2006, 24(16): 2563-2569.
16. COHEN M H, JOHNSON J R, FAZDUR R, et al. Food and Drug Administration drug approval summary: temozalamide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme [J]. Clin Cancer Res, 2005, 11(19Pt1): 6767-6771.
17. STUPP R, HEGI M E, MASON W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial [J]. Lancet Oncol, 2009, 10(5): 459-466.
18. TAPHOORN M J, STUPP R, COENS C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial [J]. Lancet Oncol, 2005, 6(12): 937-944.
19. CAVALIERE R, WEN P Y, SCHIFF D. Novel therapies for malignant gliomas [J]. Neurol Clin, 2007, 25(4): 1141-1171.
20. BRANDES A A, BASSO U, RENI M, et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia [J]. J Clin Oncol, 2004, 22 (9): 1598-1604.
21. REARDON D A, RICH J N, FRIEDMAN H S, et al. Recent advances in the treatment of malignant astrocytoma [J]. J Clin Oncol, 2006, 24(8): 1253-1265.
22. VAN DEN BENT M J, HEGI M E, STUPP R, et al. Recent developments in the use of chemotherapy in brain tumours [J]. Eur J Cancer, 2006, 42(5): 582-588. (Pubitemid 43343679)
23. VAN RIJN J, HEIMANS J J, VAN DEN BERG J, et al. Survival of human glioma cells treated with various combination of temozolomide and X-rays [J]. Int J Radiat Oncol Biol Phys, 2000, 47 (3): 779-784.
24. STUPP R, GANDER M, LEYVRAZ S, et al. Current and future developments in the use of temozolomide for the treatment of brain tumours [J]. Lancet Oncol, 2001, 2(9): 552-560.
25. HEGI M E, DISERENS A C, GORLIA T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma [J]. N Engl J Med, 2005, 352(10): 997-1003.
26. HEGI M E, DISERENS A C, GODARD S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransterase promoter methylation in glioblastoma patients treated with temozolomide [J]. Clin Cancer Res, 2004, 10 (6): 1871-1874.
27. ESTELLER M, GARCIA-FONCILLAS J, ANDION E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J]. N Engl J Med, 2000, 343 (19): 1350-1354.
28. 6-alkylguanine-DNA alkyltransterase activity with protracted temozolomide schedules [J]. Br J Cancer, 2003, 88(7): 1004-1011.